P Palthera

Common questions

FOX04-DRI — questions, answered plainly.

6 research-context questions about FOX04-DRI. Answers stay neutral and reference what is published in the peer-reviewed literature — no dosing, no human-use guidance, no extrapolation beyond what the cited studies report.

  1. 01

    What is FOX04-DRI?

    FOX04-DRI (FOXO4-D-Retro-Inverso) is a synthetic D-retro-inverso peptide designed by the Peter de Keizer group to interfere with the FOXO4-p53 interaction in senescent cells. The D-retro-inverso configuration is intended to extend protease resistance compared with the L-peptide.

  2. 02

    Is FOX04-DRI FDA-approved?

    No. FOX04-DRI is preclinical only — no FDA, MHRA, or EMA approval exists, and no peer-reviewed human clinical trials are indexed on PubMed.

  3. 03

    What does the cited FOX04-DRI research show?

    Born 2023 (Circulation, PMID 36515093) reports attenuated pulmonary hypertension and senescence markers in a bleomycin mouse model of pulmonary fibrosis. Zhang 2020 (Aging, PMID 31959736) reports clearance of senescent Leydig cells and partial restoration of testosterone secretion in aged C57BL/6 mice.

  4. 04

    What is the mechanism of FOX04-DRI?

    It is reported to compete with endogenous FOXO4 for binding to p53 in senescent cells, releasing p53 to the nucleus and triggering apoptosis selectively in cells with a senescence-associated FOXO4-p53 retention pattern.

  5. 05

    What model types are the studies in?

    All cited studies are preclinical — rodent in vivo work (bleomycin mouse pulmonary fibrosis, aged C57BL/6 mice) and in vitro Leydig-cell senescence assays. No human cohorts have been published.

  6. 06

    What are the evidence caveats for FOX04-DRI?

    No controlled human trials are indexed on PubMed. Senolytic off-target effects on non-senescent cell populations require further independent characterisation. Findings are model-specific and are not extrapolated to therapeutic use.

Important

These answers are not medical advice.

FOX04-DRI is referenced in research literature only. Palthera does not provide dosage, cycling, stacking, or injection guidance, and content is not intended to support consumer or therapeutic use. Speak to a qualified clinician for any health decisions.